Jakub Tvrdoň

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 3

Top Topics

Combination Therapy

Glycemic Control

Ejection Fraction

Top Venues

Cancer immunology, immunotherapy : CII

This page only lists publications with an associated author ORCID identifier.

Publications

Anna Siemiątkowska, Maciej Bryl, Katarzyna Kosicka-Noworzyń, Jakub Tvrdoň, Iwona Gołda-Gocka, Franciszek K Główka
Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab. Cancer immunology, immunotherapy : CII (2023)
Anna Siemiątkowska, Maciej Bryl, Katarzyna Kosicka-Noworzyń, Jakub Tvrdoň, Iwona Gołda-Gocka, Franciszek K Główka
Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab. Cancer immunology, immunotherapy : CII (2023)
Anna Siemiątkowska, Maciej Bryl, Katarzyna Kosicka-Noworzyń, Jakub Tvrdoň, Iwona Gołda-Gocka, Aleksander Barinow-Wojewódzki, Franciszek K Główka
Serum sCD25 Protein as a Predictor of Lack of Long-Term Benefits from Immunotherapy in Non-Small Cell Lung Cancer: A Pilot Study. Cancers 13 (15) (2021)